Furthermore, AZD1480 potently inhibited the in vivo growth of TPC-1 xenografts, resulting in tumor regression, while the tumors from AZD6244- treated mice grew slightly more than the control tumors, suggesting that treating RET-mutated thyroid cancers with this inhibitor may promote tumor growth. This evidence concerns the gene RET and thyroid gland carcinoma.